Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel
Research conducted on osteoarthritis in cats
Study aims to improve diagnosis and treatment

Researchers at the University of Montreal's Quebec Research Group in Animal Pharmacology have attempted to better the ability to diagnose and treat osteoarthritis in cats.

"Osteoarthritis frequently affects cats' elbows, backs and hips and joints in the hind limbs, and its prevalence increases dramatically with age," said lead author Eric Troncy of the university's Faculty of Veterinary Medicine. He added that despite the prevalence of the condition, improvements are needed in its diagnosis and treatment.

"We used our knowledge of cat behaviour and worked with experts in human osteoarthritis to develop a diagnosis tool and test an effective medication: meloxicam."

During the study 120 cats were examined by researchers, 39 of which were believed to be suffering from osteoarthritis. In order to evaluate the pain levels of the 39 sufferers, researchers measured their kinetic gait analysis - which reveals impairments in the limbs, their daily activity as recorded by an accelerometer, and their sensitivity to touch - measured by testing the level of pressure required for the cat to withdraw its paw.

For 74 days, a placebo was administered to a control group, while the remaining animals were given different doses of meloxicam, an anti-inflammatory drug already used in the treatment of other animals. According to researchers, no side effects were experienced, and the drug provided varying levels of pain relief depending on the dosage given.  Professor Troncy said: "Cats that were treated with the high dosage continued to enjoy pain relief for five weeks after dosage stopped."

The drug however, did not appear to reduce pain associated with touch, such as stroking. The same flaw, according to researchers, occurs in hypersensitive osteoarthritic humans who are being treated with anti-inflammatory drugs. Despite this, Troncy added: "The development of adapted therapy protocols to correctly treat arthritis associated with chronic pain will provide a better quality of life particularly in older cats and will in turn have a direct impact on owners, as their cat will be more active and sociable."

Researchers are now looking at how brain scans could further improve our understanding of pain in cats, particularly with regard to the neurophysiological hypersensitive process. Meloxicam is to be considered for use in cats by the Europe Medicines Agency in April of this year.

Become a member or log in to add this story to your CPD history

Practices urged to audit neutering data

News Story 1
 RCVS Knowledge has called on vet practices to audit their post-operative neutering outcomes.

It follows the release of the 2024 NASAN benchmarking report, which collates data from neutering procedures performed on dogs, cats and rabbits.

The benchmarking report enables practices in the UK and Ireland to compare their post-operative outcomes to the national average. This includes the rate of patients lost to follow-up, which in 2024 increased to 23 per cent.

Anyone from the practice can submit the data using a free template. The deadline for next report is February 2026.

Visit the RCVS Knowledge website to complete an audit. 

Click here for more...
News Shorts
UK's BSE risk status downgraded

The WOAH has downgraded the UK's international risk status for BSE to 'negligible'.

Defra says that the UK's improved risk status recognises the reputation for having the highest standards for biosecurity. It adds that it demonstrates decades of rigorous animal control.

Outbreaks of Bovine Spongiform Encephalopathy, also known as mad cow disease, have previously resulted in bans on Britain's beef exports.

The UK's new status could lead to expanded trade and better confidence in British beef.

Christine Middlemiss, the UK's chief veterinary officer, said: "WOAH's recognition of the UK as negligible risk for BSE is a significant milestone and is a testament to the UK's strong biosecurity measures and the hard work and vigilance of farmers and livestock keepers across the country who have all played their part in managing the spread of this disease.